Assessing 2-Month Clinical Prognosis In Patients With Solid Tumors: First Results Of Pronopall Study.

6047 Background: in 2008, we published in our results of a prognostic score defined by 4 factors (Karnofsky index, number of metastatic sites, serum albumin and LDH levels) in a population of 177 hospitalized patients in two hospitals (Assessing 2-Month Clinical Prognosis in Hospitalized Patients With Advanced Solid Tumors - Anne-Claire Barbot, Pascale Mussault, Pierre Ingrand and al. J Clin Oncol - vol 26, p 2358-2543. 2008.). Albumin cutoff is 33 g/l and LDH cutoff is 600 ui/l. This score defined 3 different patients populations: A: low score (0 to 3), B: intermediate score (4 to 7) and C : high score (8 to 10). The survival rates at 2 months were 92.2% ± 3.8 (population A), 42.7% ± 5.2 (population B) and 8.3% ± 4.6 (population C). Methods: In order to validate this score, we decided to start a second study in a large multicentric trial with a high proportion of out-patients. Results: Between October 2009 and October 2010, 302 patients were included from 16 institutions. Inclusion criteria: adults patients with a solid tumor in palliative setting and with one or more of the three following criteria: life expectancy less than 6 months, PS ≥ 2, evidence of progressive disease during palliative chemotherapy. All patients signed an informed consent. At this time,146 (48%) patients are evaluable for this first analysis. 13 patients are not eligible. Median age 64 years [37-87], women 60%, men 40%. PS 0-1 (43%), PS 2 (40%), PS 3-4 (17%). The most frequent primary sites: breast (39%), colon/rectum (23%), lung (15%), pancreas (10,5%), others (12,5%). One metastatic site (31%), two (37%), more than two (33%). Median LDH level: 362 ui/l [118-1,314]. Median level of serum albumin was 36 g/l [20-54]. According the prognostic score, the 2-month survival rate and the median survival were 87% and 306 days [195-417] (population A, 72 patients), 60% and 75 days [53-97] (population B, 62 patients) and 18% and 15 days [7-23] (population C, 12 patients). These three populations are statistically different (p<0.0001). Conclusions: PRONOPALL confirms the three prognotic profiles defined by combination of theses four factors and is useful in daily practice.